146 related articles for article (PubMed ID: 30060548)
1. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.
MacNeill AL; Weishaar KM; Séguin B; Powers BE
Viruses; 2018 Jul; 10(8):. PubMed ID: 30060548
[TBL] [Abstract][Full Text] [Related]
2. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Urbasic AS; Hynes S; Somrak A; Contakos S; Rahman MM; Liu J; MacNeill AL
Am J Vet Res; 2012 Aug; 73(8):1252-61. PubMed ID: 22849686
[TBL] [Abstract][Full Text] [Related]
3. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
Viruses; 2020 May; 12(5):. PubMed ID: 32397134
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.
Gentschev I; Adelfinger M; Josupeit R; Rudolph S; Ehrig K; Donat U; Weibel S; Chen NG; Yu YA; Zhang Q; Heisig M; Thamm D; Stritzker J; Macneill A; Szalay AA
PLoS One; 2012; 7(5):e37239. PubMed ID: 22615950
[TBL] [Abstract][Full Text] [Related]
6. Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma.
Ashton LV; Weishaar KM; Séguin B; MacNeill AL
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760788
[TBL] [Abstract][Full Text] [Related]
7. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
8. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.
Béguin J; Gantzer M; Farine I; Foloppe J; Klonjkowski B; Maurey C; Quéméneur É; Erbs P
Sci Rep; 2021 Jan; 11(1):2209. PubMed ID: 33500518
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
Stanford MM; Barrett JW; Nazarian SH; Werden S; McFadden G
J Virol; 2007 Feb; 81(3):1251-60. PubMed ID: 17108021
[TBL] [Abstract][Full Text] [Related]
10. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
[TBL] [Abstract][Full Text] [Related]
11. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.
Béguin J; Nourtier V; Gantzer M; Cochin S; Foloppe J; Balloul JM; Laloy E; Tierny D; Klonjkowski B; Quemeneur E; Maurey C; Erbs P
BMC Vet Res; 2020 Aug; 16(1):307. PubMed ID: 32843040
[TBL] [Abstract][Full Text] [Related]
12. Progress of oncolytic viruses in sarcomas.
Lettieri CK; Hingorani P; Kolb EA
Expert Rev Anticancer Ther; 2012 Feb; 12(2):229-42. PubMed ID: 22316371
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic myxoma virus: the path to clinic.
Chan WM; Rahman MM; McFadden G
Vaccine; 2013 Sep; 31(39):4252-8. PubMed ID: 23726825
[TBL] [Abstract][Full Text] [Related]
15. Metabolic signatures associated with oncolytic myxoma viral infections.
Mahar R; Ragavan M; Chang MC; Hardiman S; Moussatche N; Behar A; Renne R; Merritt ME
Sci Rep; 2022 Jul; 12(1):12599. PubMed ID: 35871072
[TBL] [Abstract][Full Text] [Related]
16. The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas.
MacNeill AL
Vet Comp Oncol; 2020 Mar; 18(1):36-42. PubMed ID: 31618515
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
18. Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.
Irwin CR; Favis NA; Agopsowicz KC; Hitt MM; Evans DH
PLoS One; 2013; 8(12):e84134. PubMed ID: 24391902
[TBL] [Abstract][Full Text] [Related]
19. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer.
Villa NY; Franco LS; McFadden G
Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033
[TBL] [Abstract][Full Text] [Related]
20. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M; Guegan JP; Spalato-Ceruso M; Peyraud F; Kind M; Vanhersecke L; Le Loarer F; Perret R; Cantarel C; Bellera C; Bessede A; Italiano A
Mol Cancer; 2024 Feb; 23(1):38. PubMed ID: 38378555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
